Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy
Status:
Available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Gastroparesis is a digestive disorder in which motility of the stomach is either slowed or
absent. The gastroparesis prevents normal digestion from occurring. The purpose of this study
is to provide oral Domperidone offered under the U.S. Food and Drug Administration (FDA)
expanded access program, to patients that, based on the treating doctor's assessment, could
benefit from , a prokinetic effect for the relief of refractory gastroesophageal reflux
disease with upper gastrointestinal (GI) symptoms, gastroparesis, and chronic constipation.